31 results on '"De Nicola S."'
Search Results
2. T.07.4: ACTIVE HCV OR HBV INFECTION DOES NOT IMPACT ON CLINICAL OUTCOMES IN PATIENTS WITH HEPATOCELLULAR CARCINOMA.
3. OC.18.2: EMERGING METABOLIC AND ALCOHOLIC ETIOLOGIES IN LIVER CIRRHOSIS ARE RELATED TO HIGH RATE OF RECURRENCE AFTER FIRST EPISODE OF DECOMPENSATION.
4. OC.16.6: APPLICATION OF MACHINE LEARNING MODEL-3P TO PREDICT PORTAL HYPERTENSION IN PATIENT WITH HEPATOCELLULAR CARCINOMA.
5. Myosteatosis is not associated with complications or survival in HCC patients undergoing transarterial embolization.
6. High Incidence of sepsis caused by MDR bacteria in patients undergoing Percutaneous biliary drainage for the treatment of biliary obstruction.
7. Liver transplant candidates and SARS-CoV-2 infection: Results from an Italian multicenter cohort.
8. Liver transplant recipients with Covid-19: results from an Italian multicenter cohort.
9. COVID-19-related thrombotic microangiopathy in a cirrhotic patient.
10. Clinical presentation and etiological spectrum of idiopathic non-cirrhotic portal hypertension (INCPH): data from the Italian Registry.
11. HEV infection: an emerging disease. One year observation in a tertiary care center in Milan.
12. Risk and outcome of hepatitis B virus (HBV) reactivation during chronic hepatitis C treatment with direct-acting antivirals (DAAs) in patients with HCV-related advanced fibrosis: A single-center experience.
13. Changes of indications for liver transplantation in the era of direct acting antiviral therapy in Europe.
14. Transjugular intrahepatic portosystemic shunt is a safe and effective approach in cirrhotic patients with splanchnic vein thrombosis.
15. TM6SF2 and MBOAT7 genotype to determine alcohol-related liver damage in patients with HCV chronic hepatitis.
16. A multicentre prospective study response to treatment in genotype 3 and 1b infected patients with sickest liver cirrhosis: SVR 4 is not a reliable measure.
17. The role of serum alphafetoprotein determination in HCV-cirrhosis after antiviral treatment.
18. ITPA deficiency does not predict anaemia during Ribavirin containing DAA all oral regimens for HCV.
19. Missense variant in interferon-λ4 gene identifies HCV-1 infected patients carrying the unfavorable IL28B (T) allele with improved viral kinetics.
20. Linkage between interferon-λ4 and IL28B polymorphisms in HCV-4 patients treated with pegylated interferon and ribavirin.
21. OC-21 The association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent.
22. T-31 Effect of the PNPLA3 I148M polymorphism on the outcome of peg-interferon plus ribavirin treatment in chronic hepatitis C.
23. OC-31 Low rates of SVR to peg-interferon plus ribavirin in HCV genotype 1 IL28B rs12979860 CC cirrhotic patients without rapid virological response.
24. OC7 AN IL28B POLYMORPHISM PREDICTS PEGYLATED INTERFERON PLUS RIBAVIRIN TREATMENT OUTCOME IN CHRONIC HEPATITIS C GENOTYPE 4.
25. P.1.29: A SUSTAINED VIROLOGICAL RESPONSE TO INTERFERON PREVENTS INSULIN RESISTANCE IN CHRONIC HEPATITIS C PATIENTS.
26. T-42 A sustained virological response to interferon prevents insulin resistance in chronic hepatitis C patients.
27. T-36 Fibrosis progression in patients with chronic hepatitis C is not influenced by IL28B polymorphisms.
28. P.130 SAFETY AND EFFICACY OF PEG-IFN/RBV THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C AND HIGH TITRES OF SERUM AUTOANTIBODIES: A SUB-ANALYSIS OF THE MIST STUDY.
29. OC.03.3 INSULIN RESISTANCE DOES NOT PREDICT A RESPONSE TO PEGYLATED INTERFERON PLUS RIBAVIRIN IN CHRONIC HEPATITIS C PATIENTS: A SUB-ANALYSIS OF THE MIST STUDY.
30. F.N.29 INSULIN RESISTANCE DOES NOT PREDICT A RESPONSE TO PEGYLATED INTERFERON PLUS RIBAVIRIN IN CHRONIC HEPATITIS C PATIENTS: A SUB-ANALYSIS OF THE MIST STUDY.
31. T.N.38 SAFETY AND EFFICACY OF PEG-IFN/RBV THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C AND HIGH TITRES OF SERUM AUTOANTIBODIES: A SUB-ANALYSIS OF THE MIST STUDY.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.